Test drug SHR-A1811 for gynecologic cancers
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests SHR-A1811, a cancer medicine, in people with advanced or returning cervical, ovarian, or endometrial cancer. It may help shrink tumors, depending on whether you meet study safety and eligibility requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are willing to join and sign the informed consent form (ICF).
- You have measurable cancer on scan or exams that can be followed over time.
- Your daily activity level is good (ECOG 0–1, meaning fully active or limited but able to care for yourself).
- You can be expected to live at least 12 weeks.
- Your cancer type is advanced cervical cancer, recurrent ovarian cancer, or endometrial cancer.
- You do not have certain key safety issues (brain/spread to the brain causing symptoms, serious heart problems, active infections, active hepatitis B/C, active tuberculosis, or certain autoimmune conditions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
This trial tests a new drug called SHR-A1811 for ovarian cancer. It may help people whose cancer can be measured on scans and who are still well enough to do daily activities.
This trial tests a new drug, SHR-A1811, that targets a protein called HER2 found on some cervical cancer cells. It's for women whose cervical cancer has returned or spread and is not responding to other treatments.
This study tests whether a new drug combination called SHR-A1811 can help people with cervical cancer that has come back or spread. It aims to find a better treatment option for those who have limited choices.
This trial is testing a new drug called SHR-A2102 against standard chemotherapy for people with advanced cervical cancer that has not responded to platinum-based chemotherapy and an immunotherapy (PD-1 or PD-L1 inhibitor). The goal is to see if the new drug works better and what side effects it may cause.
This study tests a new drug called SHR-A1811 in patients with advanced breast cancer that has a protein called HER2. The drug may help slow or stop cancer growth in patients who haven't had too many prior treatments.
Hear when a new Gynaecological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.